Consensus Panel Recommendation for Incorporating Lipoprotein-Associated Phospholipase A2 Testing into Cardiovascular Disease Risk Assessment Guidelines

Davidson, Michael; Corson, Marshall A.; Alberts, Mark J.; Anderson, Jeffrey L.; Gorelick, Philip B.; Jones, Peter H.; Lerman, Amir; McConnell, Joseph P.; Weintraub, Howard

doi:10.1016/j.amjcard.2008.04.019

Cited by 141 publications

(113 citation statements)

References 34 publications

Supporting

Mentioning

102

Contrasting

Unclassified

Order By: Relevance

“…Separate analysis of the association between marker levels and outcome category was performed using (1) threshold levels defined by the top quartile of levels within the study population, and (2) using previously reported threshold levels for general cardiovascular risk for LpPLA 2 -M and CRP (there is no currently accepted threshold value for LpPLA 2 -A). Both 200 ng/mL and 235 ng/mL have been recommended as appropriate threshold levels for LpPLA 2 -M. 8,9 We therefore included analysis using both of these cut points. For CRP, a threshold value of 300 g/dL has been recommended.…”

Section: Discussionmentioning

confidence: 99%

Lipoprotein-Associated Phospholipase A ₂ and C-Reactive Protein for Risk-Stratification of Patients With TIA

Cucchiara

Messé

Sansing

et al. 2009

Stroke

View full text Add to dashboard Cite

Background and Purpose-Lipoprotein-associated phospholipase A 2 (Lp-PLA 2 ) is a marker of unstable atherosclerotic plaque, and is predictive of both primary and secondary stroke in population-based studies. Methods-We conducted a prospective study of patients with acute TIA who presented to the ED. Clinical risk scoring using the ABCD 2 score was determined and Lp-PLA 2 mass (LpPLA 2 -M) and activity (LpPLA 2 -A) and high-sensitivity C-reactive protein (CRP) were measured. The primary outcome measure was a composite end point consisting of stroke or death within 90 days or identification of a high-risk stroke mechanism requiring specific early intervention (defined as Ն50% stenosis in a vessel referable to symptoms or a cardioembolic source warranting anticoagulation

show abstract

Section: Discussionmentioning

confidence: 99%

Lipoprotein-Associated Phospholipase A ₂ and C-Reactive Protein for Risk-Stratification of Patients With TIA

Cucchiara

Messé

Sansing

et al. 2009

Stroke

View full text Add to dashboard Cite

show abstract

“…The lipoprotein phospholipase A 2 belongs to a subgroup of the Ca 2+ independent PLA 2 family with a unique substrate preference for lysophospholipids, and thus is mainly involved in atherosclerotic processes. Lp-PLA 2 is responsible for generating two proinflammatory mediators following the oxidation of LDL: lysophosphatidylcholine and oxidized fatty acid, and thus is significantly associated with cardiovascular diseases and ischemic stroke (5). The cut off value defined in clinical guidelines for the management of cardiovascular disease is set at 200 ng/mL (6).…”

Section: Discussionmentioning

confidence: 99%

“…Lp-PLA 2 shows mainly proinflammatory and oxidative activities preferably associated with cardiovascular disease (5). The association of Lp-PLA 2 with bone resorption is not yet well known, and thus it seems interesting to analyze the serum levels of Lp-PLA 2 in patients with impaired bone density.…”

Section: Introductionmentioning

confidence: 99%

Lipoprotein-Associated Phospholipase A2 Is Increased in Patients with Impaired Bone Density

Kotaška¹,

Kolarova²,

Jedličková³

et al. 2014

Journal of Medical Biochemistry

View full text Add to dashboard Cite

Summary Background: Increased levels of lipoprotein-associated phospholipase A2 are associated with atherosclerosis, and may contribute to cardiac disease. The aim of this study was to analyze serum levels of lipoprotein phospholipase A2 (Lp-PLA2) in patients with impaired bone resorption and correlate the findings with markers of bone metabolism (osteocalcin) and other biochemical markers (cholesterol, low density lipoprotein, triacylglycerols). Methods: Serum Lp-PLA2 was measured by a turbidimetric method in a group of currently treated 85 patients with impaired bone resorption and in a control group of 46 healthy individuals. Serum triacylglycerols was measured by the electrochemiluminescence immunoassay. Cholesterol, low density lipoprotein and triacylglycerols were measured by commercially available enzymatic assays. Bone density was investigated by dual energy X-ray densitometry performed on the lower spine and hips. Results: Concentrations of LP-PLA2 were significantly elevated in the patients with bone resorption compared to the control group of healthy individuals (225 ng/mL vs. 192 ng/mL, p>0.001) with the highest difference in patients with a T score below –2.5 SD (227 vs. 192 ng/mL). Serum levels of Lp-PLA2 also negatively correlated with decreased levels of serum osteocalcin in patients, and a significant difference in Lp-PLA2 (p=0.02) levels was observed between the control group and group with low levels of osteocalcin. Elevated Lp-PLA2 levels were significantly associated with the therapeutic procedures used, but not with age, gender and concentration of lipids. Conclusions: Lipoprotein-associated phospholipase A2 seems to play an important role also in bone metabolism.

show abstract

“…Also the NRI was modest, being 1.1% in the entire cohort and 8.8% in the subjects at intermediate risk (45). To date, Lp-PLA2 testing is not recommended in low-risk populations as a screening tool, but it could be recommended in patients at moderate risk, determined as having simply two risk factors and high 10-year risk (patients with coronary artery disease (CAD) or CAD risk equivalents) (69). Secretory phospholipase A2 (sPLA2) is a Ca 2 _ -dependent enzyme belonging to the group of acute-phase reactants (70) which produces free fatty acid and lysophospholipid from membrane phospholipids (71).…”

Section: Introductionmentioning

confidence: 99%

From circulating biomarkers to genomics and imaging in the prediction of cardiovascular events in the general population

et al. 2011

View full text Add to dashboard Cite

From circulating biomarkers to genomics and imaging in the prediction of cardiovascular events in the general population. General rights Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.• Users may download and print one copy of any publication from the public portal for the purpose of private study or research.• You may not further distribute the material or use it for any profit-making activity or commercial gain • You may freely distribute the URL identifying the publication in the public portal Take down policy If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim. Abstract Cardiovascular disease (CVD) is the leading cause of death and disability worldwide. In the last decades numerous markers have been considered and investigated for the prediction of CV events, but only a few of them resulted in improved global risk assessment beyond traditional risk factors when incorporated into coronary evaluation scores. Recent genetic studies have pointed out a few but consistent loci or genes which are independently associated with CV risk. The idea is fascinating that these genetic markers could lead to improved individual CV risk assessment and tailored pharmacological interventions. In this brief review we will not make a systematic review of all non-genetic and genetic markers of CV risk but we will try to make a brief overview of the most interesting ones with the aim to underline potential ' pros ' and ' cons ' of their implementation in clinical practice. From circulating biomarkers to genomics and imaging in the prediction of cardiovascular events in the general population

show abstract

Consensus Panel Recommendation for Incorporating Lipoprotein-Associated Phospholipase A2 Testing into Cardiovascular Disease Risk Assessment Guidelines

Cited by 141 publications

References 34 publications

Lipoprotein-Associated Phospholipase A ₂ and C-Reactive Protein for Risk-Stratification of Patients With TIA

Lipoprotein-Associated Phospholipase A ₂ and C-Reactive Protein for Risk-Stratification of Patients With TIA

Lipoprotein-Associated Phospholipase A2 Is Increased in Patients with Impaired Bone Density

From circulating biomarkers to genomics and imaging in the prediction of cardiovascular events in the general population

Contact Info

Product

Resources

About

Consensus Panel Recommendation for Incorporating Lipoprotein-Associated Phospholipase A2 Testing into Cardiovascular Disease Risk Assessment Guidelines

Cited by 141 publications

References 34 publications

Lipoprotein-Associated Phospholipase A 2 and C-Reactive Protein for Risk-Stratification of Patients With TIA

Lipoprotein-Associated Phospholipase A 2 and C-Reactive Protein for Risk-Stratification of Patients With TIA

Lipoprotein-Associated Phospholipase A2 Is Increased in Patients with Impaired Bone Density

From circulating biomarkers to genomics and imaging in the prediction of cardiovascular events in the general population

Contact Info

Product

Resources

About

Lipoprotein-Associated Phospholipase A ₂ and C-Reactive Protein for Risk-Stratification of Patients With TIA

Lipoprotein-Associated Phospholipase A ₂ and C-Reactive Protein for Risk-Stratification of Patients With TIA